| First Author | So WY | Year | 2013 |
| Journal | Diabetes | Volume | 62 |
| Issue | 11 | Pages | 3751-9 |
| PubMed ID | 23897951 | Mgi Jnum | J:208934 |
| Mgi Id | MGI:5565409 | Doi | 10.2337/db13-0645 |
| Citation | So WY, et al. (2013) High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling. Diabetes 62(11):3751-9 |
| abstractText | Circulating fibroblast growth factor 21 (FGF21) levels are elevated in diabetic subjects and correlate directly with abnormal glucose metabolism, while pharmacologically administered FGF21 can ameliorate hyperglycemia. The pancreatic islet is an FGF21 target, yet the actions of FGF21 in the islet under normal and diabetic conditions are not fully understood. This study investigated the effects of high glucose on islet FGF21 actions in a diabetic mouse model by investigating db/db mouse islet responses to exogenous FGF21, the direct effects of glucose on FGF21 signaling, and the involvement of peroxisome proliferator-activated receptor gamma (PPARgamma) in FGF21 pathway activation. Results showed that both adult db/db mouse islets and normal islets treated with high glucose ex vivo displayed reduced beta-klotho expression, resistance to FGF21, and decreased PPARgamma expression. Rosiglitazone, an antidiabetic PPARgamma ligand, ameliorated these effects. Our data indicate that hyperglycemia in type 2 diabetes mellitus may lead to FGF21 resistance in pancreatic islets, probably through reduction of PPARgamma expression, which provides a novel mechanism for glucose-mediated islet dysfunction. |
